Enveric Biosciences(US:ENVB)2021-03-26 19:30Company Overview & Strategy - Enveric Biosciences focuses on developing FDA-approved therapeutic solutions using natural compounds to address side effects of cancer therapy, targeting unmet medical needs in supportive care [5] - The company's strategy involves identifying promising natural compounds, conducting rigorous scientific evaluation, and partnering for commercial opportunities [12, 13, 14, 15, 16] - Enveric Biosciences aims for a time- and cost-efficient path to commercialization through combination therapies and strategic investments [5] Financial Status & Key Accomplishments - As of March 2021, Enveric Biosciences has over $20 million in cash and no debt [19] - The company raised over $20 million in capital [19] - Enveric Biosciences started trading on Nasdaq in December 2020 [19] Pipeline & Partnerships - Enveric Biosciences is developing a pipeline of novel therapies for radiodermatitis, glioblastoma, and chemotherapy-induced neuropathy [25] - The company has an exclusive agreement with PureForm Global to support cannabinoid clinical programs [19, 36] - Enveric Biosciences acquired an exclusive license from Diverse Biotech for 5 molecules, primarily dermatology-focused [40] Market & Unmet Needs - Radiodermatitis affects approximately 95% of all cancer patients receiving radiation therapy [27] - Chemotherapy-induced neuropathy has a 68% incidence at 3 months [31] - Glioblastoma Multiforme (GBM) affects 22,000 adults in the US each year, with 15,000 resulting in death [35]